Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary ...
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 ...
Acquired synthetic royalties on two approved products, Syndax and Incyte’s Niktimvo (chronic graft-versus-host disease) and Ascendis’ Yorvipath (hypoparathyroidism ... from future transactions) ...